MOTIVATION LETTER The Conjunctive Consolidation Threshold model, a tripartite pharmacological framework for reward-memory encoding prevention, addresses a fundamental gap in addiction treatment: no existing therapy directly prevents the consolidation of drug-reward memories. My three sole-authored preprints on OSF and Zenodo, including a formal mathematical specification and a Bayesian population dynamics architecture with clinical trial design, demonstrate that triple-target pharmacotherapy can reduce encoding probability from 0.855 to 0.122, an 85.8 percent reduction with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed using ODE/RK45 and Bayesian MCMC validation. The U.S. Mission to Tunisia Annual Program Statement for Fiscal Year 2026 seeks health innovation and economic opportunity partnerships. Tunisia faces rising substance use disorders among youth, with limited access to computational screening tools and pharmacotherapy optimization. My open-source platforms IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions, and GATE for BCI neural-stimulation safety evaluation are Apache 2.0 licensed and deployable in low-resource settings. These tools require no proprietary hardware and can be adapted for Tunisian patient populations using local genomic and pharmacological data. I am an independent Nigerian researcher, B.Pharm from the University of Ibadan with a German-equivalent grade of 1.9, PCN-licensed pharmacist, and current National Product Manager at Synthcare. My collaborators include Kent Berridge at Michigan, Samuel Gershman at Harvard who endorsed my arXiv submission, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. A provisional patent on CCT core architecture is filed for Q3 2026. My review article is under review at Neuroscience and Biobehavioral Reviews, and a co-authored paper is under review at Alcohol. This grant would fund a pilot adaptation of IMPRINT and TOPOLOGIX for Tunisian substance use disorder populations, establish a computational pharmacology training module for Tunisian early-career researchers, and support travel for in-person collaboration with Tunisian institutions. The CCT model's mathematical specificity and open-source implementation make it directly transferable to North African clinical settings without expensive infrastructure. I seek to demonstrate that independent researchers from African countries can produce globally competitive computational neuroscience outputs and deploy them regionally. RESEARCH STATEMENT The Conjunctive Consolidation Threshold model proposes that reward-memory encoding requires simultaneous activation above a threshold across three neural systems: dopaminergic salience signaling, glutamatergic plasticity at hippocampal-striatal synapses, and noradrenergic arousal modulation. No single-target intervention can prevent encoding because compensatory mechanisms maintain conjunctive activation. The CCT framework specifies that triple-target pharmacotherapy must achieve simultaneous suppression of all three systems within a 15-minute therapeutic window to prevent memory consolidation. The formal mathematical specification, deposited at OSF 10.17605/OSF.IO/EMY4U, models each system as a coupled differential equation system solved via Runge-Kutta 45. The Bayesian population dynamics architecture at Zenodo 10.5281/zenodo.20492472 incorporates hierarchical priors from human pharmacokinetic data and simulates clinical trial outcomes under adaptive randomization. Results show that triple-target therapy reduces encoding probability from 0.855 to 0.122, with super-additivity of 12.8 percentage points beyond additive effects. All five pre-registered hypotheses were confirmed. IMPRINT is a computational screening platform that takes patient demographic, genetic, and substance use history inputs and outputs an addiction-liability score calibrated against published longitudinal cohorts. TOPOLOGIX applies persistent homology and bipartite simplicial complexes to drug-protein interaction networks, identifying off-target cardiotoxicity risks such as hERG binding. A minimum viable product for hERG cardiotoxicity screening is completed. GATE evaluates BCI neural-stimulation safety using biophysical neuron models in NEURON and Brian2, simulating current spread and tissue heating. For Tunisia, I propose three specific aims. First, adapt IMPRINT for Tunisian substance use patterns by incorporating local pharmacogenetic data on CYP2D6 and CYP3A4 polymorphisms, which affect metabolism of opioids and benzodiazepines. Second, deploy TOPOLOGIX to screen existing Tunisian pharmacopeia compounds for polypharmacology interactions relevant to the CCT triple-target profile. Third, train two Tunisian early-career researchers in computational pharmacology workflows including ODE modeling, Bayesian MCMC, and topological data analysis using open-source toolchains. The technical infrastructure is already built. Python with scipy, numpy, PyMC, and pandas handles all modeling. TDA uses Ripser and Gudhi. Molecular dynamics uses GROMACS and AutoDock. All code is version-controlled on GitHub under github.com/AmunRaPtah. The Bayesian MCMC validation used 10,000 posterior samples with R-hat convergence diagnostics below 1.01. The ODE solver used adaptive timestepping with tolerance 1e-8. This work has been endorsed by Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. A provisional patent on CCT core architecture is filed for Q3 2026. The review article is under review at Neuroscience and Biobehavioral Reviews. A co-authored paper is under review at Alcohol. BUDGET NARRATIVE Total requested: 49,850 USD over 12 months. Personnel: 18,000 USD. Stipend for two Tunisian early-career researchers at 750 USD per month for 12 months each. This covers their time for training and collaborative research on IMPRINT and TOPOLOGIX adaptation. Equipment: 8,500 USD. One workstation with 64 GB RAM and NVIDIA RTX 4090 for molecular dynamics simulations and Bayesian MCMC sampling. Current hardware in Lagos is insufficient for large-scale GROMACS runs. Travel: 7,500 USD. Two round-trip flights Lagos to Tunis at 1,500 USD each. Per diem for 30 days total at 150 USD per day. Accommodation for 30 days at 50 USD per day. This supports in-person collaboration with Tunisian institutions for data collection and model validation. Software and data: 4,500 USD. Access to Tunisian national health databases for pharmacogenetic data. Subscription to PubChem and ChEMBL APIs for compound screening. Cloud computing credits for parallel MCMC runs on AWS. Publication and dissemination: 5,000 USD. Open-access publication fees for two papers in Neuroscience and Biobehavioral Reviews or equivalent. Conference travel to present results at Society for Neuroscience or Computational Neuroscience meeting. Indirect costs: 6,350 USD. Calculated at 12.5 percent of direct costs per U.S. Mission guidelines. TIMELINE Months 1-3: Establish collaboration agreement with Tunisian institution. Obtain ethics approval for retrospective pharmacogenetic data analysis. Install and test IMPRINT and TOPOLOGIX on local hardware. Begin training of two Tunisian researchers in Python, ODE modeling, and TDA. Months 4-6: Adapt IMPRINT for Tunisian substance use patterns. Incorporate CYP2D6 and CYP3A4 polymorphism data. Run TOPOLOGIX screening of Tunisian pharmacopeia compounds. Generate initial polypharmacology profiles. Months 7-9: Conduct Bayesian MCMC simulations of CCT model with Tunisian pharmacogenetic parameters. Validate against published North African pharmacokinetic studies. Prepare manuscript for submission. Months 10-12: Submit two manuscripts to peer-reviewed journals. Present results at one international conference. Deliver final report to U.S. Mission to Tunisia. Release adapted IMPRINT and TOPOLOGIX versions as open-source tools. CHECKLIST - [ ] Complete Grants.gov registration for Eniola Ayodele Olutogun - [ ] Obtain DUNS number or UEI for independent researcher status - [ ] Secure letter of collaboration from Tunisian institution (identify target institution) - [ ] Obtain letter of endorsement from Kent Berridge, University of Michigan - [ ] Obtain letter of endorsement from Samuel Gershman, Harvard University - [ ] Upload CV with ORCID 0009-0001-9272-6735 and GitHub github.com/AmunRaPtah - [ ] Upload three preprints: OSF 10.17605/OSF.IO/KG7B5, OSF 10.17605/OSF.IO/EMY4U, Zenodo 10.5281/zenodo.20492472 - [ ] Upload provisional patent documentation for CCT core architecture - [ ] Upload B.Pharm certificate and transcript from University of Ibadan - [ ] Upload PCN pharmacist license - [ ] Complete budget narrative with detailed justification - [ ] Complete timeline with milestones - [ ] Submit SF-424 form - [ ] Submit SF-424A budget form - [ ] Submit SF-424B assurances form - [ ] Submit abstract (250 words maximum) - [ ] Submit project narrative (15 pages maximum) - [ ] Submit bibliography - [ ] Submit letters of support from collaborators - [ ] Submit current and pending support form EDITOR NOTES - Eligibility risk: The APS is for U.S. Mission to Tunisia and may require applicant to be Tunisian or affiliated with a Tunisian institution. Verify if independent Nigerian researchers are eligible. If not, identify a Tunisian co-PI or host institution before submission. - Fact verification: Confirm that the provisional patent is filed as stated for Q3 2026. If not yet filed, adjust timeline and remove claim. Verify that the review article is actually under review at Neuroscience and Biobehavioral Reviews. - Gap: No specific Tunisian institution or collaborator is named in the profile. The applicant must identify and secure a letter of collaboration from a Tunisian university, hospital, or research center before submission. Suggested targets: University of Tunis El Manar Faculty of Medicine, Institut Pasteur de Tunis, or Centre National de Pharmacovigilance. - Gap: The budget narrative assumes 12.5 percent indirect costs, but the APS may have a different negotiated rate or cap. Verify the specific indirect cost policy for this grant mechanism. If no negotiated rate exists, use 10 percent de minimis. - Gap: The applicant is not yet enrolled in an MSc program. The APS may require enrollment in a degree program or affiliation with an accredited institution. Verify eligibility for independent researchers without current academic affiliation. If required, establish affiliation with ZYCO as a registered research organization in Nigeria.